ALK and non-small cell lung carcinoma: Dual targeting of the ErbB pathway with the pan-HER inhibitor and Wnt/β-catenin pathway with tankyrase1/2 inhibitors (TNKS1/2) almost completely prevented the appearance of alectinib-induced DTP cells in ALK + NSCLC [63].